The chief data reporter for the Financial Times discusses how he considers the use of text, color, and annotation to aid ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market insights reveal exciting opportunities. See more.

June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...

Nearly 1 in 5 packaged foods and drinks from major U.S. brands contain synthetic dyes, with products aimed at children—like ...

-- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET-- SAN DIEGO, June 9, 2025 ...

The American Academy of Neurology issues new guidelines to help clinicians navigate the use of unproven neurologic therapies lacking FDA approval or strong evidence.

FY25 results highlight a strong turnaround with robust sales, margin improvements, and store growth. See more on DG stock ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease. This decision ...

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...